Fiche publication
Date publication
mai 2016
Journal
Leukemia & lymphoma
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FORNECKER Luc-Matthieu
,
Dr DAGUINDAU Etienne
Tous les auteurs :
Gac AC, Azar N, Daguindau E, Cartron G, Fornecker LM, Gyan E, Broussais-Guillaumot F, Garidi R, Choufi B, Chantepie SP, Béné MC, Guiéze R, Bijou F, Gressin R, Amorim S, Damaj G
Lien Pubmed
Résumé
Bendamustine is used in the treatment of different relapsing or refractory subtypes of lymphoma. Its impact on the yield of peripheral blood stem cells is not well known. Twenty three patients who received bendamustine followed immediately or after another chemotherapy by stem cell mobilization (SCM) were included. The patients were divided into two groups: group 1 (n=17), in whom SCM was performed immediately after bendamustine chemotherapy, and group 2 (n=6), in whom SCM was performed after another cycle of chemotherapy. The success rate of mobilization after Bendamustine+/-plerixafor was 36% (eight cytapheresis succeeded for a total number of 22 cytapheresis); and 75% after other approaches (chemotherapy based or steady state) used for patients who received bendamustine previously. Although bendamustine used alone was not an effective drug to mobilize stem cells, this agent does not seem to have detrimental effects on subsequent SCM.
Mots clés
Adult, Aged, Antineoplastic Agents, Alkylating, administration & dosage, Bendamustine Hydrochloride, administration & dosage, Combined Modality Therapy, Female, Hematopoietic Stem Cell Mobilization, methods, Humans, Lymphoma, diagnosis, Male, Middle Aged, Neoplasm Staging, Peripheral Blood Stem Cells, cytology, Retreatment, Retrospective Studies
Référence
Leuk. Lymphoma. 2016 May;57(5):1149-53
